309 related articles for article (PubMed ID: 9886427)
1. IFN-gamma increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats.
Egwuagu CE; Sztein J; Mahdi RM; Li W; Chao-Chan C; Smith JA; Charukamnoetkanok P; Chepelinsky AB
J Immunol; 1999 Jan; 162(1):510-7. PubMed ID: 9886427
[TBL] [Abstract][Full Text] [Related]
2. Expression of interferon-gamma in the lens exacerbates anterior uveitis and induces retinal degenerative changes in transgenic Lewis rats.
Egwuagu CE; Mahdi RM; Chan CC; Sztein J; Li W; Smith JA; Chepelinsky AB
Clin Immunol; 1999 May; 91(2):196-205. PubMed ID: 10227812
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-gamma-dependent mechanism.
Hoey S; Grabowski PS; Ralston SH; Forrester JV; Liversidge J
J Immunol; 1997 Nov; 159(10):5132-42. PubMed ID: 9366443
[TBL] [Abstract][Full Text] [Related]
4. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens.
Caspi RR; Roberge FG; Chan CC; Wiggert B; Chader GJ; Rozenszajn LA; Lando Z; Nussenblatt RB
J Immunol; 1988 Mar; 140(5):1490-5. PubMed ID: 3346541
[TBL] [Abstract][Full Text] [Related]
5. High IFN-alpha expression is associated with the induction of experimental autoimmune uveitis (EAU) in Fischer 344 rat.
Hu YJ; Zang L; Wu YD; Sun B
Cell Res; 2001 Dec; 11(4):293-300. PubMed ID: 11794322
[TBL] [Abstract][Full Text] [Related]
6. Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice.
Caspi RR; Chan CC; Grubbs BG; Silver PB; Wiggert B; Parsa CF; Bahmanyar S; Billiau A; Heremans H
J Immunol; 1994 Jan; 152(2):890-9. PubMed ID: 8283058
[TBL] [Abstract][Full Text] [Related]
7. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
[TBL] [Abstract][Full Text] [Related]
8. Genetic susceptibility to experimental autoimmune uveoretinitis in the rat is associated with an elevated Th1 response.
Caspi RR; Silver PB; Chan CC; Sun B; Agarwal RK; Wells J; Oddo S; Fujino Y; Najafian F; Wilder RL
J Immunol; 1996 Sep; 157(6):2668-75. PubMed ID: 8805672
[TBL] [Abstract][Full Text] [Related]
9. Rodent models of experimental autoimmune uveitis.
Agarwal RK; Caspi RR
Methods Mol Med; 2004; 102():395-419. PubMed ID: 15286397
[TBL] [Abstract][Full Text] [Related]
10. The role of the ICOS/B7RP-1 T cell costimulatory pathway in murine experimental autoimmune uveoretinitis.
Usui Y; Akiba H; Takeuchi M; Kezuka T; Takeuchi A; Hattori T; Okunuki Y; Yamazaki T; Yagita H; Usui M; Okumura K
Eur J Immunol; 2006 Nov; 36(11):3071-81. PubMed ID: 17039566
[TBL] [Abstract][Full Text] [Related]
11. CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.
Takeuchi A; Usui Y; Takeuchi M; Hattori T; Kezuka T; Suzuki J; Okunuki Y; Iwasaki T; Haino M; Matsushima K; Usui M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3753-60. PubMed ID: 16186359
[TBL] [Abstract][Full Text] [Related]
12. WSX-1 plays a significant role for the initiation of experimental autoimmune uveitis.
Sonoda KH; Yoshimura T; Takeda A; Ishibashi T; Hamano S; Yoshida H
Int Immunol; 2007 Jan; 19(1):93-8. PubMed ID: 17118967
[TBL] [Abstract][Full Text] [Related]
13. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
14. IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice.
Jiang HR; Wei X; Niedbala W; Lumsden L; Liew FY; Forrester JV
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):177-82. PubMed ID: 11133864
[TBL] [Abstract][Full Text] [Related]
15. Peripheral expression of rod photoreceptor arrestin induces an epitope-specific, protective response against experimental autoimmune uveoretinitis.
McPherson SW; Roberts JP; Gregerson DS
Curr Eye Res; 2005 Jun; 30(6):491-502. PubMed ID: 16020282
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis.
Suzuki J; Sakai J; Okada AA; Takada E; Usui M; Mizuguchi J
Graefes Arch Clin Exp Ophthalmol; 2002 Apr; 240(4):314-21. PubMed ID: 11981647
[TBL] [Abstract][Full Text] [Related]
17. Treatment of experimental autoimmune uveoretinitis with atorvastatin and lovastatin.
Kohno H; Sakai T; Saito S; Okano K; Kitahara K
Exp Eye Res; 2007 Mar; 84(3):569-76. PubMed ID: 17208229
[TBL] [Abstract][Full Text] [Related]
18. The protective effect of IFN-gamma in experimental autoimmune diseases: a central role of mycobacterial adjuvant-induced myelopoiesis.
Matthys P; Vermeire K; Heremans H; Billiau A
J Leukoc Biol; 2000 Oct; 68(4):447-54. PubMed ID: 11037964
[TBL] [Abstract][Full Text] [Related]
19. Changes in ocular mast cell numbers and histamine distribution during experimental autoimmune uveitis.
Lee CH; Lang LS; Orr EL
Reg Immunol; 1993; 5(2):106-13. PubMed ID: 8217552
[TBL] [Abstract][Full Text] [Related]
20. Type I interferons as immunoregulatory molecules; implications for therapy in experimental autoimmune uveoretinitis.
Mizuguchi J; Takeuchi M; Usui M
Arch Immunol Ther Exp (Warsz); 2002; 50(4):243-54. PubMed ID: 12371620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
